Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study.
A randomized double-blind cross-over study was conducted to determine the inhibitory effects of acetylsalicylic acid (ASA), ticlopidine (TP) and cilostazol (OPC-13013; in the following briefly called CS), a new antithrombotic agent on platelet functions ex vivo. Nine patients with cerebral thrombosis were enrolled in this study. Patients were given each of the three drugs for one week in a complete cross-over design according to a randomization schedule, followed by a wash-out period with a placebo for one week. It was found that CS and TP significantly inhibited platelet aggregation induced by ADP. Collagen- and arachidonic acid-induced platelet aggregation was all inhibited by CS, TP and ASA. Duncan's multiple range test to compare the anti-platelet effects of the three drugs revealed that: CS greater than ASA and TP greater than ASA in inhibiting ADP-induced platelet aggregation and CS greater than TP and ASA greater than TP in inhibiting arachidonic acid-induced platelet aggregation. These results may suggest that CS is superior to ASA and TP in inhibiting platelet aggregation ex vivo.
D000368:Aged; D001241:Aspirin / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects*; D000077407:Cilostazol; D004311:Double-Blind Method; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010978:Platelet Factor 4 / Q000032:analysis; D011897:Random Allocation; D013777:Tetrazoles / Q000494:pharmacology*; D013988:Ticlopidine / Q000494:pharmacology*; D001620:beta-Thromboglobulin / Q000032:analysis
D001393:Azoles; D005343:Fibrinolytic Agents; D013777:Tetrazoles; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D000077407:Cilostazol; D013988:Ticlopidine; D001241:Aspirin